What the Longevity Panel Claimed About Living to 150

At a TIME100 Health Leadership Forum panel in New York on Sept. 10, Harvard Medical School professor David Sinclair repeated his belief that the first person who will live to 150 is already alive. Asked to explain, he pointed to the rapid changes in artificial intelligence and healthcare over the past five years, arguing that children born today will reach the 22nd century with access to medical technologies that are currently unimaginable.

The panel also included neuroscientist Jennifer Garrison, who focuses on women’s health and ovarian biology, and Jack Jia, founder and CEO of the telehealth platform Musely. Garrison said differences between male and female bodies could offer medical levers for everyone, noting that female bodies appear to fight viruses better than male bodies for reasons researchers do not yet fully understand.

Jia said Musely expanded beyond skincare after his wife struggled to find effective treatment for melasma. He argued that the healthcare system is built to treat the seriously ill rather than to support proactive health, and said the company has broadened into resources and treatments for longevity. The discussion also addressed a surge in longevity testing, with Garrison cautioning that many marketed products are poorly supported by evidence or are outright pseudoscience.

Why the 150-Year Claim and the Longevity Market Need More Evidence

Why Sinclair’s 150-Year Claim Is a Bet on Unknown Technology

Sinclair’s statement is best understood as a bet on the speed of innovation, not a testable medical forecast. He explicitly links the possibility of a 150-year lifespan to technologies that “we literally cannot even imagine now.” That means the claim rests on future breakthroughs in AI and medicine rather than on any demonstrated biological pathway today. It is a striking framing from a prominent longevity researcher, but it offers no mechanism or timetable.

The Data Deficit Behind Women’s Longevity Claims

Garrison’s most concrete warning is about data. She said male-female biological research is not years or decades but “generations behind,” a systemic gap that limits the ability to tailor medicines. Her example—female bodies appearing better at fighting viruses for reasons not fully understood—shows that even basic mechanisms remain unresolved. That gap is especially relevant to longevity products aimed at women, where marketing often outpaces the evidence.

Musely, Longevity Testing and the Credibility Problem

Jia’s presence on the panel reflects a commercial shift, not just a scientific debate. Musely started with skincare-like telehealth care and is expanding into proactive health and longevity after his wife struggled with melasma. At the same time, both Garrison and Sinclair expressed concern about the longevity testing boom: Garrison said much of it is poorly supported or pseudoscience, while Sinclair worried that unproven peptide injections and drugs are becoming more common. His view that regulation was once too strict and has now swung too far in the other direction captures the unresolved tension between early access and patient safety.

What Consumers Should Ask Before Buying Longevity Tests and Treatments

  • Before paying for a longevity test or supplement, ask for peer-reviewed evidence. Garrison said many products in the space are “poorly supported by evidence or outright pseudoscience,” so marketing claims alone are not enough.
  • Treat female-specific longevity marketing with extra caution. Garrison described the volume of messaging aimed at women as “crazy” while noting that the underlying biological data remains generations behind.
  • Do not self-experiment with unproven peptides or drugs. Sinclair said fringe self-injection is becoming more common; he supports trying unproven options only with a doctor, when standard treatments have failed and downside appears low.